Table 2 Occurrence of drugs in different disorders.

From: Possible adverse events of imidazole antifungal drugs during treatment of vulvovaginal candidiasis: analysis of the FDA Adverse Event Reporting System

Drug

Age

Case

PT name

ROR

Pregnancy, puerperium and perinatal conditions

 A

19–39

5

Foetal death

10.28 (24.92, 4.24)

 B

19–39

9

Abortion spontaneous

19.62 (41.34, 9.31)

 D

19–39

8

Premature rupture of membranes

22.91 (46.45, 11, 3)

 C

0–18

6

Drug withdrawal syndrome neonatal

20.14 (45.92, 8.83)

 C

0–18

7

Sepsis neonatal

123.71 (274.76, 55.7)

 C

19–39

7

Premature baby

7.54 (15.93, 3.57)

 C

19–39

13

Premature labour

4.96 (8.59, 2.86)

 C

40–59

4

Abortion spontaneous

5.98 (16.02, 2.24)

Renal and urinary disorders

 A

0–18

3

Dysuria

28.46 (90.85, 8.92)

 A

19–39

8

Pelvic pain

4.05 (8.18, 2.01)

 A

19–39

4

Renal failure

4.51 (12.1, 1.68)

 A

19–39

3

Urinary retention

7.46 (23.29, 2.39)

 A

40–59

19

Acute kidney injury

10.45 (16.57, 6, 59)

 A

40–59

22

Chronic kidney disease

19.96 (30.71, 12.97)

 A

40–59

8

End stage renal disease

31.35 (63.37, 15.51)

 A

40–59

5

Nephrogenic anaemia

55.42 (135.11, 22.73)

 A

40–59

6

Pelvic pain

18.69 (41.96, 8.32)

 A

40–59

3

Polyuria

19.46 (60.85, 6.22)

 A

40–59

18

Renal failure

8.66 (13.9, 5.4)

 A

40–59

4

Renal impairment

3.93 (10.52, 1.47)

 A

40–59

4

Renal injury

6.63 (17.78, 2.47)

 A

40–59

4

Renal tubular necrosis

21.92 (58.92, 8.15)

 A

40–59

5

Tubulointerstitial nephritis

18.85 (45.67, 7.78)

 A

 ≥ 60

8

Bladder transitional cell carcinoma

291.66 (613.67, 138.62)

 A

 ≥ 60

3

Chromaturia

4.05 (12.6, 1.3)

 A

 ≥ 60

18

Chronic kidney disease

11.63 (18.6, 7.27)

 A

 ≥ 60

5

Dysuria

4.34 (10.47, 1.8)

 A

 ≥ 60

4

End stage renal disease

10.57 (28.33, 3.95)

 A

 ≥ 60

6

Hyperparathyroidism secondary

59.47 (134.37, 26.32)

 A

 ≥ 60

8

Incontinence

19.25 (38.78, 9.56)

 A

 ≥ 60

4

Nephrogenic anaemia

21.35 (57.33, 7.95)

 A

 ≥ 60

10

Pollakiuria

7.01 (13.1, 3.75)

 A

 ≥ 60

5

Renal injury

7.67 (18.51, 3.18)

 A

 ≥ 60

5

Tubulointerstitial nephritis

8.54 (20.63, 3.54)

 A

 ≥ 60

6

Urinary incontinence

5.11 (11.43, 2.29)

 A

 ≥ 60

4

Urinary retention

4.49 (12.02, 1.68)

 B

 ≥ 60

6

Acute kidney injury

4.41 (9.97, 1.95)

 B

 ≥ 60

4

Renal failure

3.36 (9.06, 1.25)

 B

 ≥ 60

6

Urinary tract infection

3.07 (6.94, 1.36)

 D

19–39

5

Renal failure

6.88 (16.69, 2.84)

 D

40–59

8

Acute kidney injury

4.1 (8.26, 2.04)

 D

40–59

3

Chromaturia

5.95 (18.56, 1.91)

 D

40–59

14

Chronic kidney disease

11.92 (20.32, 6.99)

 D

40–59

3

Haematuria

7.07 (22.05, 2.27)

 D

40–59

6

Pelvic pain

17.95 (40.29, 8)

 D

40–59

11

Renal failure

4.99 (9.08, 2.74)

 D

40–59

3

Renal injury

4.76 (14.85, 1.53)

 D

 ≥ 60

17

Chronic kidney disease

11.36 (18.41, 7.01)

 D

 ≥ 60

6

End stage renal disease

16.51 (37.01, 7.37)

 D

 ≥ 60

4

Nephrogenic anaemia

22.1 (59.36, 8.23)

 D

 ≥ 60

3

Renal injury

4.74 (14.76, 1.52)

 C

0–18

3

Renal failure

4.92 (15.47, 1.56)

 C

19–39

19

Dysuria

12.27 (19.42, 7.76)

 C

40–59

4

Cystitis haemorrhagic

52.26 (141.78, 19.27)

 C

40–59

9

Dysuria

8.78 (16.98, 4.54)

 C

40–59

8

Haematuria

13.4 (26.98, 6.65)

 C

 ≥ 60

4

Chronic kidney disease

2.88 (7.7, 1.08)

 C

 ≥ 60

10

Dysuria

10.02 (18.75, 5.36)

 C

 ≥ 60

18

Haematuria

19.03 (30.48, 11.88)

 C

 ≥ 60

4

Pollakiuria

3.17 (8.47, 1.18)

  1. A, clotrimazole; B, econazole; C, miconazole; D, ketoconazole.